Barchart on MSN

Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?

Pfizer (PFE) has reportedly decided to sell its entire remaining stake in BioNTech (BNTX), showing a lack of confidence in ...

A Look at BioNTech (NasdaqGS:BNTX) Valuation Following Pfizer’s Share Sale Announcement

BioNTech (NasdaqGS:BNTX) shares caught investors’ attention after Pfizer revealed plans to sell its remaining stake in the company through an overnight block trade. This announcement prompted a wave ...

BioNTech Reports Q3 2025 Financials and Raises Revenue Guidance

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech Reports Q3 2025 Financial Results with Revenue Growth Amid Operating Loss

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Watch Drug Stocks After Pfizer Divestiture, Merck Acquisition

Since May 2025, Pfizer (PFE) traded in a narrow range between $24.00 and $26. The company does not have shareholder ...

Pfizer is said to divest remaining stake in BioNTech

BioNTech (BNTX) stock slips as Pfizer (PFE) plans to sell its remaining stake in the COVID-19 vaccine developer in a ...
Fintel on MSN

HC Wainwright & Co. Maintains BioNTech SE - Depositary Receipt (BNTX) Buy Recommendation

Fintel reports that on November 10, 2025, HC Wainwright & Co. maintained coverage of BioNTech SE - Depositary Receipt ...

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and ...